col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


140 Results       Page 1

 [1] 
American Association for the Advancement of Science (AAAS): Science Translational Medicine
  original article Date Title Authors   All Authors
1 [GO] 2024―Jul―24 Adjuvantation of a SARS-CoV-2 mRNA vaccine with controlled tissue-specific expression of an mRNA encoding IL-12p70 Byron Brook, Valerie Duval, Soumik Barman, Lauren Speciner, Cali Sweitzer, Asad Khanmohammed, et al. (+11)
2 [GO] 2024―Jul―17 Comparative single-cell analysis reveals IFN-γ as a driver of respiratory sequelae after acute COVID-19 Chaofan Li, Wei Qian, Xiaoqin Wei, Harish Narasimhan, Yue Wu, Mohd Arish, et al. (+8)
3 [GO] 2024―Jul―03 PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections Ryan M. Shepard, Anghesom Ghebremedhin, Isaraphorn Pratumchai, Sally R. Robinson, Courtney Betts, Jingjing Hu, et al. (+36)
4 [GO] 2024―Jul―03 Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection Michael J. Peluso, Dylan Ryder, Robert R. Flavell, Yingbing Wang, Jelena Levi, Brian H. LaFranchi, et al. (+29)
5 [GO] 2024―Jun―26 AZD3152 neutralizes SARS-CoV-2 historical and contemporary variants and is protective in hamsters and well tolerated in adults Yingyun Cai, Seme Diallo, Kim Rosenthal, Kuishu Ren, Daniel J. Flores, Andrew Dippel, et al. (+31)
6 [GO] 2024―Jun―12 Heterotypic immunity from prior SARS-CoV-2 infection but not COVID-19 vaccination associates with lower endemic coronavirus incidence David J. Bean, Janet Monroe, Yan Mei Liang, Ella Borberg, Yasmeen Senussi, Zoe Swank, et al. (+4)
7 [GO] 2024―May―22 The oral nucleoside prodrug GS-5245 is efficacious against SARS-CoV-2 and other endemic, epidemic, and enzootic coronaviruses David R. Martinez, Fernando R. Moreira, Nicholas J. Catanzaro, Meghan V. Diefenbacher, Mark R. Zweigart, Kendra L. Gully, et al. (+26)
8 [GO] 2024―May―15 Comparative analysis of SARS-CoV-2 neutralization titers reveals consistency between human and animal model serum and across assays Barbara Mühlemann, Samuel H. Wilks, Lauren Baracco, Meriem Bekliz, Juan Manuel Carreño, Victor M. Corman, et al. (+40)
9 [GO] 2024―Apr―17 Host-microbe multiomic profiling reveals age-dependent immune dysregulation associated with COVID-19 immunopathology Hoang Van Phan, Alexandra Tsitsiklis, Cole P. Maguire, Elias K. Haddad, Patrice M. Becker, Seunghee Kim-Schulze, et al. (+229)
10 [GO] 2024―Mar―13 An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations Michael Westberg, Yichi Su, Xinzhi Zou, Pinghan Huang, Arjun Rustagi, Jaishree Garhyan, et al. (+16)
11 [GO] 2024―Jan―24 SARS-CoV-2 viral clearance and evolution varies by type and severity of immunodeficiency Yijia Li, Manish C. Choudhary, James Regan, Julie Boucau, Anusha Nathan, Tessa Speidel, et al. (+27)
12 [GO] 2024―Jan―03 Adjuvanted SARS-CoV-2 spike protein vaccination elicits long-lived plasma cells in nonhuman primates Madhu Prabhakaran, Flavio Matassoli, David Leggat, Abigayle Hoover, Abhinaya Srikanth, Weiwei Wu, et al. (+21)
13 [GO] 2023―Dec―06 USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice Fabin Dang, Lei Bai, Jiazhen Dong, Xiaoping Hu, Jingchao Wang, Joao A. Paulo, et al. (+21)
14 [GO] 2023―Nov―29 T cell responses to SARS-CoV-2 infection and vaccination are elevated in B cell deficiency and reduce risk of severe COVID-19 Reza Zonozi, Lucy C. Walters, Aaron Shulkin, Vivek Naranbhai, Pravarut Nithagon, Gabriel Sauvage, et al. (+20)
15 [GO] 2023―Oct―18 Many potential pathways to future pandemic influenza David M. Morens, Jaekeun Park, Jeffery K. Taubenberger
16 [GO] 2023―Sep―27 A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus Longping V. Tse, Yixuan J. Hou, Elizabeth McFadden, Rhianna E. Lee, Trevor D. Scobey, Sarah R. Leist, et al. (+12)
17 [GO] 2023―Sep―13 Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2 Guillaume B. E. Stewart-Jones, Sayda M. Elbashir, Kai Wu, Diana Lee, Isabella Renzi, Baoling Ying, et al. (+19)
18 [GO] 2023―Sep―06 Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases Jonathan D. Herman, Caroline Atyeo, Yonatan Zur, Claire E. Cook, Naomi J. Patel, Kathleen M. Vanni, et al. (+11)
19 [GO] 2023―Aug―30 An inhaled ACE2 decoy confers protection against SARS-CoV-2 infection in preclinical models Emiko Urano, Yumi Itoh, Tatsuya Suzuki, Takanori Sasaki, Jun-ichi Kishikawa, Kanako Akamatsu, et al. (+26)
20 [GO] 2023―Aug―23 A complement atlas identifies interleukin-6-dependent alternative pathway dysregulation as a key druggable feature of COVID-19 Karel F. A. Van Damme, Levi Hoste, Jozefien Declercq, Elisabeth De Leeuw, Bastiaan Maes, Liesbet Martens, et al. (+17)
21 [GO] 2023―Aug―09 Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts Joseph W. Guarnieri, Joseph M. Dybas, Hossein Fazelinia, Man S. Kim, Justin Frere, Yuanchao Zhang, et al. (+45)
22 [GO] 2023―Jul―12 Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states Thomas R. Müller, Takuya Sekine, Darya Trubach, Julia Niessl, Puran Chen, Peter Bergman, et al. (+21)
23 [GO] 2023―May―24 A multi-specific, multi-affinity antibody platform neutralizes sarbecoviruses and confers protection against SARS-CoV-2 in vivo Clare Burn Aschner, Krithika Muthuraman, Iga Kucharska, Hong Cui, Katherine Prieto, Manoj S. Nair, et al. (+14)
24 [GO] 2023―May―10 Broadly neutralizing antibodies against sarbecoviruses generated by immunization of macaques with an AS03-adjuvanted COVID-19 vaccine Yupeng Feng, Meng Yuan, John M. Powers, Mengyun Hu, Jennifer E. Munt, Prabhu S. Arunachalam, et al. (+21)
25 [GO] 2023―Apr―19 Comparing antibody assays as correlates of protection against COVID-19 in the COVE mRNA-1273 vaccine efficacy trial David Benkeser, David C. Montefiori, Adrian B. McDermott, Youyi Fong, Holly E. Janes, Weiping Deng, et al. (+39)
26 [GO] 2023―Apr―05 Pandemic preparedness strategies must go beyond vaccines Rajesh Gupta, Lisa A. Purcell, Davide Corti, Herbert W. Virgin
27 [GO] 2023―Mar―22 Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers Pete Schmidt, Kristin Narayan, Yong Li, Chengzi I. Kaku, Michael E. Brown, Elizabeth Champney, et al. (+10)
28 [GO] 2023―Mar―15 Prior SARS-CoV-2 infection enhances and reshapes spike protein-specific memory induced by vaccination Véronique Barateau, Loïc Peyrot, Carla Saade, Bruno Pozzetto, Karen Brengel-Pesce, Mad-Hélénie Elsensohn, et al. (+22)
29 [GO] 2023―Feb―15 An inactivated NDV-HXP-S COVID-19 vaccine elicits a higher proportion of neutralizing antibodies in humans than mRNA vaccination Juan Manuel Carreño, Ariel Raskin, Gagandeep Singh, Johnstone Tcheou, Hisaaki Kawabata, Charles Gleason, et al. (+19)
30 [GO] 2023―Jan―04 Vaccination with S pan , an antigen guided by SARS-CoV-2 S protein evolution, protects against challenge with viral variants in mice Yongliang Zhao, Wenjia Ni, Simeng Liang, Lianghui Dong, Min Xiang, Zeng Cai, et al. (+17)
31 [GO] 2022―Dec―01 Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later Emma C. Milligan, Katherine Olstad, Caitlin A. Williams, Michael Mallory, Patricio Cano, Kaitlyn A. Cross, et al. (+36)
32 [GO] 2022―Nov―08 Swiss public health measures associated with reduced SARS-CoV-2 transmission using genome data Sarah A. Nadeau, Timothy G. Vaughan, Christiane Beckmann, Ivan Topolsky, Chaoran Chen, Emma Hodcroft, et al. (+42)
33 [GO] 2022―Nov―03 S-217622, a SARS-CoV-2 main protease inhibitor, decreases viral load and ameliorates COVID-19 severity in hamsters Michihito Sasaki, Koshiro Tabata, Mai Kishimoto, Yukari Itakura, Hiroko Kobayashi, Takuma Ariizumi, et al. (+16)
34 [GO] 2022―Oct―04 SARS-CoV-2 3CL pro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376 Emmanuel Heilmann, Francesco Costacurta, Seyed Arad Moghadasi, Chengjin Ye, Matteo Pavan, Davide Bassani, et al. (+9)
35 [GO] 2022―Sep―22 SARS-CoV-2 infection drives an inflammatory response in human adipose tissue through infection of adipocytes and macrophages Giovanny J. Martínez-Colón, Kalani Ratnasiri, Heping Chen, Sizun Jiang, Elizabeth Zanley, Arjun Rustagi, et al. (+12)
36 [GO] 2022―Sep―14 A shift in lung macrophage composition is associated with COVID-19 severity and recovery Steven T. Chen, Matthew D. Park, Diane Marie Del Valle, Mark Buckup, Alexandra Tabachnikova, Ryan C. Thompson, et al. (+30)
37 [GO] 2022―Sep―14 Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models Renee L. Hajnik, Jessica A. Plante, Yuejin Liang, Mohamad-Gabriel Alameh, Jinyi Tang, Srinivasa Reddy Bonam, et al. (+16)
38 [GO] 2022―Aug―17 Durable protection against the SARS-CoV-2 Omicron variant is induced by an adjuvanted subunit vaccine Prabhu S. Arunachalam, Yupeng Feng, Usama Ashraf, Mengyun Hu, Alexandra C. Walls, Venkata Viswanadh Edara, et al. (+39)
39 [GO] 2022―Jul―27 SARS-CoV-2 S2-targeted vaccination elicits broadly neutralizing antibodies Kevin W. Ng, Nikhil Faulkner, Katja Finsterbusch, Mary Wu, Ruth Harvey, Saira Hussain, et al. (+15)
40 [GO] 2022―Jul―26 SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children Yannic C Bartsch, Kerri J St Denis, Paulina Kaplonek, Jaewon Kang, Evan C Lam, Madeleine D Burns, et al. (+12)
41 [GO] 2022―Jul―21 Elevated risk of infection with SARS-CoV-2 Beta, Gamma, and Delta variant compared to Alpha variant in vaccinated individuals Stijn P. Andeweg, Harry Vennema, Irene Veldhuijzen, Naomi Smorenburg, Dennis Schmitz, Florian Zwagemaker, et al. (+80)
42 [GO] 2022―Jul―20 Dendrimer nanotherapy for severe COVID-19 attenuates inflammation and neurological injury markers and improves outcomes in a phase2a clinical trial Aaron M. Gusdon, Nauder Faraday, John S. Aita, Sunil Kumar, Ishan Mehta, HuiMahn A. Choi, et al. (+6)
43 [GO] 2022―Jul―12 A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques Joseph P. Nkolola, Jingyou Yu, Huahua Wan, Aiquan Chang, Katherine McMahan, Tochi Anioke, et al. (+11)
44 [GO] 2022―Jul―07 SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice Kenneth H. Dinnon, Sarah R. Leist, Kenichi Okuda, Hong Dang, Ethan J. Fritch, Kendra L. Gully, et al. (+39)
45 [GO] 2022―Jun―09 The anti-SARS-CoV-2 monoclonal antibody, bamlanivimab, minimally impacts the endogenous immune response to COVID-19 vaccination Robert J. Benschop, Jay L. Tuttle, Lin Zhang, Josh Poorbaugh, Nicole L. Kallewaard, Peter Vaillancourt, et al. (+10)
46 [GO] 2022―Jun―07 SARS-CoV-2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery Justin J. Frere, Randal A. Serafini, Kerri D. Pryce, Marianna Zazhytska, Kohei Oishi, Ilona Golynker, et al. (+16)
47 [GO] 2022―May―31 SARS-CoV-2 transmission, persistence of immunity, and estimates of Omicron’s impact in South African population cohorts Kaiyuan Sun, Stefano Tempia, Jackie Kleynhans, Anne von Gottberg, Meredith L McMorrow, Nicole Wolter, et al. (+15)
48 [GO] 2022―May―17 The adenosine analog prodrug ATV006 is orally bioavailable and has preclinical efficacy against parental SARS-CoV-2 and variants Liu Cao, Yingjun Li, Sidi Yang, Guanguan Li, Qifan Zhou, Jing Sun, et al. (+34)
49 [GO] 2022―May―17 Characterization of the SARS-CoV-2 B.1.621 (Mu) variant Peter J. Halfmann, Makoto Kuroda, Tammy Armbrust, James Theiler, Ariane Balaram, Gage K. Moreno, et al. (+24)
50 [GO] 2022―May―05 Adenovirus type 5 SARS-CoV-2 vaccines delivered orally or intranasally reduced disease severity and transmission in a hamster model Stephanie N. Langel, Susan Johnson, Clarissa I. Martinez, Sarah N. Tedjakusuma, Nadine Peinovich, Emery G. Dora, et al. (+5)
51 [GO] 2022―Apr―28 Mutations in the SARS-CoV-2 RNA dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms Laura J. Stevens, Andrea J. Pruijssers, Hery W. Lee, Calvin J. Gordon, Egor P. Tchesnokov, Jennifer Gribble, et al. (+11)
52 [GO] 2022―Apr―26 An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo Nariko Ikemura, Shunta Taminishi, Tohru Inaba, Takao Arimori, Daisuke Motooka, Kazutaka Katoh, et al. (+12)
53 [GO] 2022―Apr―12 Population-level implications of the Israeli booster campaign to curtail COVID-19 resurgence Nir Gavish, Rami Yaari, Amit Huppert, Guy Katriel
54 [GO] 2022―Apr―12 Multivalent designed proteins neutralize SARS-CoV-2 variants of concern and confer protection against infection in mice Andrew C. Hunt, James Brett Case, Young-Jun Park, Longxing Cao, Kejia Wu, Alexandra C. Walls, et al. (+41)
55 [GO] 2022―Apr―05 SARS-CoV-2 BA.1 variant is neutralized by vaccine booster-elicited serum, but evades most convalescent serum and therapeutic antibodies Sabrina Lusvarghi, Simon D. Pollett, Sabari Nath Neerukonda, Wei Wang, Richard Wang, Russell Vassell, et al. (+24)
56 [GO] 2022―Mar―29 mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions Paulina Kaplonek, Deniz Cizmeci, Stephanie Fischinger, Ai-ris Collier, Todd Suscovich, Caitlyn Linde, et al. (+14)
57 [GO] 2022―Mar―22 Therapeutic treatment with an oral prodrug of the remdesivir parental nucleoside is protective against SARS-CoV-2 pathogenesis in mice Alexandra Schäfer, David R. Martinez, John J. Won, Rita M. Meganck, Fernando R. Moreira, Ariane J. Brown, et al. (+22)
58 [GO] 2022―Mar―15 Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines Yannic C. Bartsch, Xin Tong, Jaewon Kang, María José Avendaño, Eileen F. Serrano, Tamara García-Salum, et al. (+8)
59 [GO] 2022―Mar―08 Characterization of immune responses in fully vaccinated individuals following breakthrough infection with the SARS-CoV-2 delta variant Ai-ris Y. Collier, Catherine M. Brown, Katherine A. McMahan, Jingyou Yu, Jinyan Liu, Catherine Jacob-Dolan, et al. (+14)
60 [GO] 2022―Mar―01 Vaccination with SARS-CoV-2 spike protein lacking glycan shields elicits enhanced protective responses in animal models Han-Yi Huang, Hsin-Yu Liao, Xiaorui Chen, Szu-Wen Wang, Cheng-Wei Cheng, Md. Shahed-Al-Mahmud, et al. (+23)
61 [GO] 2022―Feb―23 Erratum for the Research Article: “First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes” by J. J. Guthmiller, J. Han, L. Li, A. W. Freyn, S. T. H. Liu, O. Stovicek, C. T. Stamper, H. L. Dugan, M. E. Tepora, H. A. Utset, D. J. Bitar, N. J. Hamel, S. Changrob, N.-Y. Zheng, M. Huang, F. Krammer, R. Nachbagauer, P. Palese, A. B. Ward, P. C. Wilson
62 [GO] 2022―Feb―22 A homologous or variant booster vaccine after Ad26.COV2.S immunization enhances SARS-CoV-2-specific immune responses in rhesus macaques Xuan He, Malika Aid, Abishek Chandrashekar, Jingyou Yu, Katherine McMahan, Frank Wegmann, et al. (+21)
63 [GO] 2022―Feb―16 A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates M. Gordon Joyce, Hannah A. D. King, Ines Elakhal-Naouar, Aslaa Ahmed, Kristina K. Peachman, Camila Macedo Cincotta, et al. (+52)
64 [GO] 2022―Feb―15 Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection John P. Evans, Cong Zeng, Claire Carlin, Gerard Lozanski, Linda J. Saif, Eugene M. Oltz, et al. (+2)
65 [GO] 2022―Feb―09 Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity Catherine Riou, Roanne Keeton, Thandeka Moyo-Gwete, Tandile Hermanus, Prudence Kgagudi, Richard Baguma, et al. (+21)
66 [GO] 2022―Feb―09 Robust immune responses are observed after one dose of BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals Marie I. Samanovic, Amber R. Cornelius, Sophie L. Gray-Gaillard, Joseph Richard Allen, Trishala Karmacharya, Jimmy P. Wilson, et al. (+5)
67 [GO] 2022―Feb―08 A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection Panpan Zhou, Meng Yuan, Ge Song, Nathan Beutler, Namir Shaabani, Deli Huang, et al. (+17)
68 [GO] 2022―Feb―02 Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains Baoling Ying, Bradley Whitener, Laura A. VanBlargan, Ahmed O. Hassan, Swathi Shrihari, Chieh-Yu Liang, et al. (+14)
69 [GO] 2022―Feb―01 Infection or a third dose of mRNA vaccine elicit neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients Xavier Charmetant, Maxime Espi, Ilies Benotmane, Véronique Barateau, Francoise Heibel, Fanny Buron, et al. (+17)
70 [GO] 2022―Jan―26 An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice Etsuro Nanishi, Francesco Borriello, Timothy R. O’Meara, Marisa E. McGrath, Yoshine Saito, Robert E. Haupt, et al. (+40)
71 [GO] 2022―Jan―25 The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans Yueh-Ming Loo, Patrick M. McTamney, Rosalinda H. Arends, Michael E. Abram, Anastasia A. Aksyuk, Seme Diallo, et al. (+25)
72 [GO] 2022―Jan―18 Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity Saborni Chakraborty, Joseph C. Gonzalez, Benjamin L. Sievers, Vamsee Mallajosyula, Srijoni Chakraborty, Megha Dubey, et al. (+36)
73 [GO] 2022―Jan―14 Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses Benjamin L. Sievers, Saborni Chakraborty, Yong Xue, Terri Gelbart, Joseph C. Gonzalez, Arianna G. Cassidy, et al. (+16)
74 [GO] 2022―Jan―11 Predicting the mutational drivers of future SARS-CoV-2 variants of concern M. Cyrus Maher, Istvan Bartha, Steven Weaver, Julia di Iulio, Elena Ferri, Leah Soriaga, et al. (+10)
75 [GO] 2021―Dec―30 Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection Meghan S. Vermillion, Eisuke Murakami, Bin Ma, Jared Pitts, Adrian Tomkinson, Davin Rautiola, et al. (+20)
76 [GO] 2021―Dec―23 A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus William A. Fischer, Joseph J. Eron, Wayne Holman, Myron S. Cohen, Lei Fang, Laura J. Szewczyk, et al. (+13)
77 [GO] 2021―Nov―24 Erratum for the Research Article: “Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses” by E. A. Bordt, L. L. Shook, C. Atyeo, K. M. Pullen, R. M. De Guzman, M.-C. Meinsohn, M. Chauvin, S. Fischinger, L. J. Yockey, K. James, R. Lima, L. M. Yonker, A. Fasano, S. Brigida, L. M. Bebell, D. J. Roberts, D. Pepin, J. R. Huh, S. D. Bilbo, J. Z. Li, A. Kaima, D. J. Schust, K. J. Gray, D. Lauffenburger, G. Alter, A. G. Edlow
78 [GO] 2021―Oct―27 Comment on “Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2” Michael A. Martin, Katia Koelle
79 [GO] 2021―Oct―27 Response to comment on “Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2” Michael D. Nicholson, Lukas Endler, Alexandra Popa, Jakob-Wendelin Genger, Christoph Bock, Franziska Michor, Andreas Bergthaler
80 [GO] 2021―Oct―26 Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort Raphael Carapito, Richard Li, Julie Helms, Christine Carapito, Sharvari Gujja, Véronique Rolli, et al. (+58)
81 [GO] 2021―Oct―26 GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults Simone Lanini, Stefania Capone, Andrea Antinori, Stefano Milleri, Emanuele Nicastri, Roberto Camerini, et al. (+63)
82 [GO] 2021―Oct―21 Pregnancy Influences Immune Responses to SARS-CoV-2 Cristian Ovies, Eleanor C. Semmes, Carolyn B. Coyne
83 [GO] 2021―Oct―21 COVID-19 mRNA vaccines drive differential antibody Fc-functional profiles in pregnant, lactating, and non-pregnant women Caroline Atyeo, Elizabeth A. DeRiso, Christine Davis, Evan A. Bordt, Rose M. De Guzman, Lydia L. Shook, et al. (+8)
84 [GO] 2021―Oct―21 Maternal SARS-CoV-2 infection elicits sexually dimorphic placental immune responses Evan A Bordt, Lydia L Shook, Caroline Atyeo, Krista M Pullen, Rose M De Guzman, Marie-Charlotte Meinsohn, et al. (+20)
85 [GO] 2021―Oct―18 An affinity-enhanced, broadly neutralizing heavy chain-only antibody protects against SARS-CoV-2 infection in animal models Bert Schepens, Loes van Schie, Wim Nerinckx, Kenny Roose, Wander Van Breedam, Daria Fijalkowska, et al. (+57)
86 [GO] 2021―Oct―15 Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 Felice D’Agnillo, Kathie-Anne Walters, Yongli Xiao, Zong-Mei Sheng, Kelsey Scherler, Jaekeun Park, et al. (+22)
87 [GO] 2021―Sep―30 Early sample tagging and pooling enables simultaneous SARS-CoV-2 detection and variant sequencing Alon Chappleboim, Daphna Joseph-Strauss, Ayelet Rahat, Israa Sharkia, Miriam Adam, Daniel Kitsberg, et al. (+11)
88 [GO] 2021―Sep―30 AZD1222/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire Phillip A. Swanson, Marcelino Padilla, Wesley Hoyland, Kelly McGlinchey, Paul A. Fields, Sagida Bibi, et al. (+63)
89 [GO] 2021―Sep―21 Prior infection with SARS-CoV-2 WA1/2020 partially protects rhesus macaques against re-infection with B.1.1.7 and B.1.351 variants Abishek Chandrashekar, Jinyan Liu, Jingyou Yu, Katherine McMahan, Lisa H. Tostanoski, Catherine Jacob-Dolan, et al. (+26)
90 [GO] 2021―Sep―15 What have we learned from the COVID-19 plague? Stanley A. Plotkin
91 [GO] 2021―Sep―14 Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern Hyeseon Cho, Kristina Kay Gonzales-Wartz, Deli Huang, Meng Yuan, Mary Peterson, Janie Liang, et al. (+34)
92 [GO] 2021―Sep―07 Immunity elicited by natural infection or Ad26.COV2.S vaccination protects hamsters against SARS-CoV-2 variants of concern Lisa H. Tostanoski, Jingyou Yu, Noe B. Mercado, Katherine McMahan, Catherine Jacob-Dolan, Amanda J. Martinot, et al. (+24)
93 [GO] 2021―Aug―24 Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19 Monique G.P. van der Wijst, Sara E. Vazquez, George C. Hartoularos, Paul Bastard, Tianna Grant, Raymund Bueno, et al. (+39)
94 [GO] 2021―Aug―10 Two doses of the SARS-CoV-2 BNT162b2 vaccine enhances antibody responses to variants in individuals with prior SARS-CoV-2 infection Richard A Urbanowicz, Theocharis Tsoleridis, Hannah J Jackson, Lola Cusin, Joshua D Duncan, Joseph G Chappell, et al. (+13)
95 [GO] 2021―Jul―27 Intranasal ChAdOx1 nCoV-19/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models Neeltje van Doremalen, Jyothi N. Purushotham, Jonathan E. Schulz, Myndi G. Holbrook, Trenton Bushmaker, Aaron Carmody, et al. (+15)
96 [GO] 2021―Jul―27 Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates Joseph R. Francica, Barbara J. Flynn, Kathryn E. Foulds, Amy T. Noe, Anne P. Werner, Ian N. Moore, et al. (+54)
97 [GO] 2021―Jul―20 A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters Yangtao Wu, Xiaofen Huang, Lunzhi Yuan, Shaojuan Wang, Yali Zhang, Hualong Xiong, et al. (+30)
98 [GO] 2021―Jul―13 A high-throughput cell- and virus-free assay shows reduced neutralization of SARS-CoV-2 variants by COVID-19 convalescent plasma Craig Fenwick, Priscilla Turelli, Céline Pellaton, Alex Farina, Jérémy Campos, Charlène Raclot, et al. (+8)
99 [GO] 2021―Jul―07 Increasing threats from SARS-CoV-2 variants: Time to establish global surveillance Scott P. Layne, Jeffery K. Taubenberger
100 [GO] 2021―Jun―22 Undiagnosed SARS-CoV-2 Seropositivity During the First Six Months of the COVID-19 Pandemic in the United States Heather Kalish, Carleen Klumpp-Thomas, Sally Hunsberger, Holly Ann Baus, Michael P Fay, Nalyn Siripong, et al. (+47)
101 [GO] 2021―Jun―22 Key epidemiological drivers and impact of interventions in the 2020 SARS-CoV-2 epidemic in England Edward S. Knock, Lilith K. Whittles, John A. Lees, Pablo N. Perez-Guzman, Robert Verity, Richard G. FitzJohn, et al. (+25)
102 [GO] 2021―Jun―15 Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19 Mercedes Prudencio, Young Erben, Christopher P. Marquez, Karen R. Jansen-West, Camila Franco-Mesa, Michael G. Heckman, et al. (+15)
103 [GO] 2021―Jun―08 Plasma from patients with bacterial sepsis or severe COVID-19 induces production of suppressive myeloid cells from human hematopoietic progenitor cells in vitro Miguel Reyes, Michael R. Filbin, Roby P. Bhattacharyya, Abraham Sonny, Arnav Mehta, Kianna Billman, et al. (+12)
104 [GO] 2021―Jun―08 Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection Allison J. Greaney, Andrea N. Loes, Lauren E. Gentles, Katharine H.D. Crawford, Tyler N. Starr, Keara D. Malone, et al. (+2)
105 [GO] 2021―Jun―02 First exposure to the pandemic H1N1 virus induced broadly neutralizing antibodies targeting hemagglutinin head epitopes Jenna J. Guthmiller, Julianna Han, Lei Li, Alec W. Freyn, Sean T. H. Liu, Olivia Stovicek, et al. (+14)
106 [GO] 2021―May―03 COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters Guilherme Dias de Melo, Françoise Lazarini, Sylvain Levallois, Charlotte Hautefort, Vincent Michel, Florence Larrous, et al. (+15)
107 [GO] 2021―May―03 Viral genomes reveal patterns of the SARS-CoV-2 outbreak in Washington State Nicola F. Müller, Cassia Wagner, Chris D. Frazar, Pavitra Roychoudhury, Jover Lee, Louise H. Moncla, et al. (+37)
108 [GO] 2021―Apr―05 The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates Bryan E. Jones, Patricia L. Brown-Augsburger, Kizzmekia S. Corbett, Kathryn Westendorf, Julian Davies, Thomas P. Cujec, et al. (+51)
109 [GO] 2021―Mar―15 T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals Tatjana Bilich, Annika Nelde, Jonas S. Heitmann, Yacine Maringer, Malte Roerden, Jens Bauer, et al. (+9)
110 [GO] 2021―Mar―15 SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19 Juan A. Perez-Bermejo, Serah Kang, Sarah J. Rockwood, Camille R. Simoneau, David A. Joy, Ana C. Silva, et al. (+12)
111 [GO] 2021―Mar―10 Academic careers and the COVID-19 pandemic: Reversing the tide Rotonya M. Carr, Meghan B. Lane-Fall, Eugenia South, Donita Brady, Florence Momplaisir, Carmen E. Guerra, et al. (+4)
112 [GO] 2021―Feb―22 Lessons from applied large-scale pooling of 133,816 SARS-CoV-2 RT-PCR tests Netta Barak, Roni Ben-Ami, Tal Sido, Amir Perri, Aviad Shtoyer, Mila Rivkin, et al. (+11)
113 [GO] 2021―Feb―03 Development and deployment of COVID-19 vaccines for those most vulnerable Wayne C. Koff, Theodore Schenkelberg, Tere Williams, Ralph S. Baric, Adrian McDermott, Cheryl M. Cameron, et al. (+13)
114 [GO] 2021―Jan―20 Could COVID-19 eliminate the alarm clock? Jennifer M. Hurley
115 [GO] 2021―Jan―11 Single-cell RNA sequencing reveals SARS-CoV-2 infection dynamics in lungs of African green monkeys Emily Speranza, Brandi N. Williamson, Friederike Feldmann, Gail L. Sturdevant, Lizzette Pérez Pérez, Kimberly Meade-White, et al. (+9)
116 [GO] 2021―Jan―04 Stereotypic neutralizing VH antibodies against SARS-CoV-2 spike protein receptor binding domain in COVID-19 patients and healthy individuals Sang Il Kim, Jinsung Noh, Sujeong Kim, Younggeun Choi, Duck Kyun Yoo, Yonghee Lee, et al. (+13)
117 [GO] 2020―Dec―09 Convalescent plasma in COVID-19: Does use case matter? Girish N. Nadkarni
118 [GO] 2020―Dec―08 IgA dominates the early neutralizing antibody response to SARS-CoV-2 Delphine Sterlin, Alexis Mathian, Makoto Miyara, Audrey Mohr, François Anna, Laetitia Claër, et al. (+21)
119 [GO] 2020―Dec―08 Enhanced SARS-CoV-2 neutralization by dimeric IgA Zijun Wang, Julio C. C. Lorenzi, Frauke Muecksch, Shlomo Finkin, Charlotte Viant, Christian Gaebler, et al. (+14)
120 [GO] 2020―Dec―01 Lung transplantation for patients with severe COVID-19 Ankit Bharat, Melissa Querrey, Nikolay S. Markov, Samuel Kim, Chitaru Kurihara, Rafael Garza-Castillon, et al. (+9)
121 [GO] 2020―Nov―24 Genomic epidemiology of superspreading events in Austria reveals mutational dynamics and transmission properties of SARS-CoV-2 Alexandra Popa, Jakob-Wendelin Genger, Michael D. Nicholson, Thomas Penz, Daniela Schmid, Stephan W. Aberle, et al. (+32)
122 [GO] 2020―Nov―10 Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19 Yu Zuo, Shanea K. Estes, Ramadan A. Ali, Alex A. Gandhi, Srilakshmi Yalavarthi, Hui Shi, et al. (+13)
123 [GO] 2020―Oct―19 Prospects for a safe COVID-19 vaccine Barton F. Haynes, Lawrence Corey, Prabhavathi Fernandes, Peter B. Gilbert, Peter J. Hotez, Srinivas Rao, et al. (+4)
124 [GO] 2020―Sep―21 Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients Carl A. Pierce, Paula Preston-Hurlburt, Yile Dai, Clare Burn Aschner, Natalia Cheshenko, Benjamin Galen, et al. (+13)
125 [GO] 2020―Aug―19 Considering COVID-19 kidney injury Girish N. Nadkarni
126 [GO] 2020―Aug―03 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice Athri D. Rathnayake, Jian Zheng, Yunjeong Kim, Krishani Dinali Perera, Samantha Mackin, David K Meyerholz, et al. (+6)
127 [GO] 2020―Jul―27 A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples Viet Loan Dao Thi, Konrad Herbst, Kathleen Boerner, Matthias Meurer, Lukas PM Kremer, Daniel Kirrmaier, et al. (+13)
128 [GO] 2020―Jul―20 An alphavirus-derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates Jesse H. Erasmus, Amit P. Khandhar, Megan A. O’Connor, Alexandra C. Walls, Emily A. Hemann, Patience Murapa, et al. (+16)
129 [GO] 2020―Jul―01 Nanosponges intercept coronavirus infection Su Xinyi
130 [GO] 2020―Jun―22 Using influenza surveillance networks to estimate state-specific prevalence of SARS-CoV-2 in the United States Justin D. Silverman, Nathaniel Hupert, Alex D. Washburne
131 [GO] 2020―Jun―10 The story of COVID-19: A comparative analysis Shaon Sengupta
132 [GO] 2020―Jun―08 Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits Supriya Ravichandran, Elizabeth M. Coyle, Laura Klenow, Juanjie Tang, Gabrielle Grubbs, Shufeng Liu, et al. (+3)
133 [GO] 2020―Jun―03 COVID-19 diagnostics in context Ralph Weissleder, Hakho Lee, Jina Ko, Mikael J. Pittet
134 [GO] 2020―May―27 Blood-borne biomarkers may help predict COVID-19 mortality Iwijn De Vlaminck
135 [GO] 2020―May―13 COVID-19 and cancer: The bad and the ugly Ecaterina Ileana-Dumbrava
136 [GO] 2020―Apr―29 An ACE therapy for COVID-19 Christopher B. Rodell
137 [GO] 2020―Apr―29 An ounce of public health for COVID-19? Girish N. Nadkarni
138 [GO] 2020―Apr―22 Can cell therapies halt cytokine storm in severe COVID-19 patients? James Ankrum
139 [GO] 2020―Apr―06 An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice Timothy P. Sheahan, Amy C. Sims, Shuntai Zhou, Rachel L. Graham, Andrea J. Pruijssers, Maria L. Agostini, et al. (+22)
140 [GO] 2020―Mar―11 New coronavirus outbreak: Framing questions for pandemic prevention Scott P. Layne, James M. Hyman, David M. Morens, Jeffery K. Taubenberger
 [1] 

140 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec